MBX
MBX Biosciences, Inc. Common Stock
There isn't enough reported data to score MBX yet.
MBX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
MBX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
MBX PE Valuation
MBX has no meaningful PE right now: it lost money over the past year.
MBX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect MBX's losses to grow, with revenue holding steady.
MBX Earnings Per Share
MBX is still losing money, but less than at its worst: $3.03 per share over the past year, against $3.91 at its worst in late 2024.
MBX Quarterly Revenue
MBX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$36.1M | -$14.1M |
| Q2 2026 | -$23.5M | -$5.4M |
| Q1 2026 | -$20.6M | +$2.1M |
| Q4 2025 | -$19.1M | -$3M |
| Q2 2025 | -$18.1M | -$4.4M |
| Q1 2025 | -$22.7M | -$11.7M |
| Q4 2024 | -$16.1M | -$4.9M |
| Q2 2024 | -$13.7M | -$6.3M |
MBX has burned cash in almost every quarter: −$99M over the past year, against −$79M the year before.
MBX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +863K shares |
| 1 year | +45% | +15.1M shares |
| 3 years | +45% | +15.2M shares |
MBX has 49M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
MBX Net Leverage
MBX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MBX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.6 | Neutral |
| Stochastic | 26.6 | Neutral |
MBX's weekly RSI is 53 (neutral) and its Stochastic is 27 (neutral).
MBX PE vs Healthcare Sector
MBX has no meaningful PE right now: it lost money over the past year.
MBX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $53.2 | 2.6% above |
| 20 week MA | $59.2 | 7.9% below |
| 50 week MA | $44.0 | 24% above |
| 100 week MA | $28.8 | 89% above |
MBX's trend is mixed: it's above three of its four weekly moving averages, and 89% above its 100-week average.
MBX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $23.7 | $20.1 | -15% |
| 2025 | $20.1 | $30.9 | +54% |
| 2026 YTD | $30.9 | $54.5 | +76% |
MBX is up 76% so far in 2026, after finishing lower in one of the previous two years.